TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04643405
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Study: NCT00002092
Drug: Cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05826951
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol (0.8g/kg)
Study: NCT03692312
Drug: Tideglusib
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
Study: NCT04713670
Drug: (A) T-V14
Normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
Study: NCT04713670
Drug: (B) T-V7
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
Study: NCT04713670
Drug: (C) D-V14
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
Study: NCT04713670
Drug: (D) HD-V14
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
Study: NCT04713670
Drug: (F) RH-V14
Normalized name: RH-OLIGOPEPTIDE-2
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
Study: NCT06109831
Drug: SHR-1918
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1918
Study: NCT04713670
Drug: (H) T-L14
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
Study: NCT05315024
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream
Study: NCT04964479
Drug: Anlotinib Hydrochloride Capsules
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg capsule once daily
Study: NCT04964479
Drug: Pembrolizumab injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg injection once every 3 week
Study: NCT06164665
Drug: Pioglitazone 15mg
Normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
Study: NCT06513234
Drug: Orelabrutinib and obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
Study: NCT06231277
Drug: BH002
Normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
Study: NCT05295875
Drug: ALT-801
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (SC)
Study: NCT05663580
Drug: Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
Study: NCT05677282
Drug: Rifaximin 550 MG
Normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 mg as a single dose administered orally.
Study: NCT05677282
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
Study: NCT03137966
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Study: NCT04536077
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be supplied free of charge by Celldex
Study: NCT04536077
Drug: CDX-1140
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug will be supplied free of charge by Celldex
Study: NCT05565794
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
Study: NCT05505539
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intralesionally by injection
Study: NCT03806751
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Study: NCT05019729
Drug: VRC-MALMAB0114-00-AB
Normalized name: AB-8939
DrugBank: AB-8939 (DB17115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
Study: NCT05659927
Drug: MG-ZG122 Humanized Monoclonal Antibody Injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Study: NCT06555146
Drug: Semaglutide, 0.5 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 subcutaneous injection on baseline day
Study: NCT05205291
Drug: Lipopolysaccharide
Normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
Study: NCT00003858
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06556199
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
Study: NCT06556199
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
Study: NCT06556199
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
Study: NCT05532358
Drug: Fluvoxamine 100 mg QD for 5 days
Normalized name: fluvoxamine 100 MG
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anle138b (TEV-56286) as victim
Study: NCT05072938
Drug: Axid Capsule 150mg
Normalized name: Axid
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine Monotherapy
Study: NCT04776993
Drug: Methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole for 72 weeks
Study: NCT06375824
Drug: Bufei Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
Study: NCT05533164
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg rituximab in 250ml NaCl 0.9% intravenously
Study: NCT04993391
Drug: JS111(AP-L1898 Capsules)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, QD
Study: NCT04993391
Drug: JS111(AP-L1898 Capsules)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg, QD
Study: NCT04993391
Drug: JS111(AP-L1898 Capsules)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg, QD
Study: NCT04993391
Drug: JS111(AP-L1898 Capsules)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240 mg, QD
Study: NCT04993391
Drug: JS111(AP-L1898 Capsules)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 320 mg, QD
Study: NCT06125106
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
Study: NCT04234867
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily for 5 days
Study: NCT05193188
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
Study: NCT05193188
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
Study: NCT05039606
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
Study: NCT05039606
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
Study: NCT05657041
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Body weight adjusted clopidogrel dosing
Study: NCT05474001
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
Study: NCT05474001
Drug: intravenous graniseton
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 6.25mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 12.5mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 18.75mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 25.0mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 31.25mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT05924594
Drug: CTx-1301 - Dexmethylphenidate 37.5mg
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study: NCT04884997
Drug: toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: toripalimab 3mg/kg, Q2w;
Study: NCT04884997
Drug: Temozolomide Injection
Normalized name: temozolomide Injection
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150mg/m2,d1-5,Q4w
Study: NCT05659368
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tirzepatide once weekly
Study: NCT06393413
Drug: Donepezil Hydrochloride Tablets
Normalized name: Donepezil Hydrochloride Tablets
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil Hydrochloride Tablets
Study: NCT00277550
Drug: Tegaserod and Placebo
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06169891
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one s.c. injection of SSGJ-613 once, on Day 1.
Study: NCT04415333
Drug: Sodium Butyrate 5 mmol
Normalized name: butyrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
Study: NCT05276258
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
Study: NCT04415333
Drug: Sodium Butyrate 80 mmol
Normalized name: butyrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
Study: NCT00000878
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000878
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000878
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06169891
Drug: Compound Betamethasone Injection
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL i.m. once on Day 1
Study: NCT05100329
Drug: Mitoxantrone Hydrochloride Liposome injection
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
Study: NCT05623384
Drug: Mecobalamin Tablets
Normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Mecobalamin Tablets tid-8
Study: NCT04668768
Drug: Glucarpidase
Normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
Study: NCT05298163
Drug: Calcitriol capsules
Normalized name: Calcitriol Capsules
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
Study: NCT00000634
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04806919
Drug: Progesteron TID
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: increasing the dose
Study: NCT05476380
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
Study: NCT06315686
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
Study: NCT04842604
Drug: Glasdegib
Normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg or 100 mg tablet
Study: NCT04842604
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/vial powder for 25 mg/mL suspension for injection
Study: NCT04572217
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
Study: NCT04572217
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine (starting dose 8 mg, max dose 16 mg)
Study: NCT06328673
Drug: DM919
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-MICA/MICB monoclonal antibody
Study: NCT06328673
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-1 monoclonal antibody
Study: NCT04713644
Drug: Standardized Propofol Administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
Study: NCT05553717
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 12.5mg\\12hr
Study: NCT06091735
Drug: OSS
Normalized name: Gossypol
DrugBank: Gossypol (DB13044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental
Study: NCT06091735
Drug: OSS+Linzess
Normalized name: Linzess
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: experimental
Study: NCT06091735
Drug: PEG-Interferon Alfa
Normalized name: PEG-Interferon alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05314998
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
Study: NCT05314998
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
Study: NCT05314998
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
Study: NCT05314998
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
Study: NCT05314998
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
Study: NCT06113211
Drug: Narcotic pain medication
Normalized name: lidocaine / menthol Medicated Patch [LidoPro Pain Relieving Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
Study: NCT06113211
Drug: Nonnarcotic pain medications
Normalized name: lidocaine / menthol Medicated Patch [LidoPro Pain Relieving Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
Study: NCT05432284
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure THC vapor